The time to develop CNS metastatic disease seems to be shorter in patients with HER2/neu-positive brain lesions, demonstrating the importance of evaluating the HER2/neu status early in the diagnosis of breast cancer in order to provide information on the patient's prognosis and to assist clinical decision-making. The gene discussed is ERBB2; the disease is breast carcinoma.